Plus Therapeutics, Inc. announced its financial results for Q4 and the year ended December 31, 2025, highlighting a $15 million public offering and advancements in its CNSide and REYOBIQ programs. The company aims for significant growth in 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.